• Ferrostatins, Lipid Damage, and Ferroptosis

  2026-10-07

  Skouta and colleagues showed that ferrostatin-1 protects against ferroptotic cell death primarily by suppressing oxidative lipid damage, rather than by broadly removing all reactive oxygen species. By testing disease-relevant cellular models and developing a mechanistic framework for ferrostatin activity, the study connected membrane lipid peroxidation with diverse neurodegenerative and kidney-related phenotypes while guiding the design of improved analogues.

• CGP 55845 Hydrochloride in GABAB Research

  2026-10-07

  CGP 55845 hydrochloride is a supplier-described selective GABAB receptor antagonist that can help frame questions about presynaptic inhibition and neurotransmitter release modulation. However, the supplied 2025 Glia study investigated astrocytic GAT-3 in the entorhinal cortex–dentate gyrus circuit, not CGP 55845. This overview compares those mechanisms, distinguishes reported findings from interpretation, and outlines evidence limitations. The compound’s published relevance to astrocytic GAT-3, contextual memory, hypoglycemia, and clinical applications remains unestablished.

• Patient-Derived Gastric Cancer Assembloids

  2026-10-06

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell populations. The model revealed that stromal context can reshape gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor heterogeneity, resistance, and personalized treatment.

• Verteporfin (CL 318952): Evidence and Research Context

  2026-10-06

  Verteporfin is best established as a light-activated therapy for ocular neovascularization, while proposed light-independent effects on YAP/TEAD signaling, autophagy, apoptosis, and chemoresistance remain model-dependent. This overview compares clinical, mechanistic, and translational evidence and defines the main limits on interpretation.

• Hypoxia-Activated Molecular Glue for Cancer Therapy

  2026-10-05

  Li and colleagues report BNNC, a hypoxia-responsive photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumor-associated conditions. The study reports enhanced DNA damage, apoptosis, and tumor-growth suppression compared with either component alone, while also identifying important questions about selectivity, exposure, and translation.

• Thioguanine: Evidence, Mechanisms, and Limits

  2026-10-05

  Thioguanine, also called 6-thioguanine, is a thiopurine compound studied in inflammatory bowel disease treatment, oncology, and antiviral research. The available supplied evidence requires careful separation of direct findings from claims made in a supplier description. In particular, a cited hepatocellular carcinoma study investigated SGI-1027, a distinct DNA methyltransferase inhibitor, not thioguanine. This overview compares the provenance and strength of the available evidence, explains plausible research questions, and defines the limits of extrapolating cell-based findings to clinical outcomes.

• Sulfamonomethoxine: Aquatic Toxicity and Evidence

  2026-10-04

  Sulfamonomethoxine (SMM) is a veterinary sulfonamide antibiotic whose environmental significance depends on both antimicrobial use and aquatic exposure. This overview examines the published toxicity evidence, compares endpoints across species, and defines the limits of conclusions that can be drawn from a single laboratory study.

• COVID-19 mRNA Vaccines and Cancer Immunotherapy

  2026-10-03

  A study by Grippin et al. links recent COVID-19 mRNA vaccination with improved outcomes during immune checkpoint inhibition, supported by retrospective patient analyses and mechanistic mouse experiments. The work suggests that an existing mRNA vaccine platform may help reshape tumor immunity, but the clinical association remains preliminary and requires prospective validation.

• BCECF for Causal pH Mapping in Efferocytosis

  2026-10-02

  BCECF enables calibrated extracellular pH mapping in macrophage efferocytosis and neuropathic pain experiments. This article shows how a ratiometric pH readout can distinguish microenvironmental effects from the AMPK/Gas6-MerTK/SOCS3 mechanism reported in ozone research.

• PDHA1 Succinylation in Cholangiocarcinoma Immunity

  2026-10-01

  The reference study identifies PDHA1 lysine 83 succinylation as a metabolic–immune switch in cholangiocarcinoma: it increases PDH activity, promotes α-ketoglutarate accumulation, and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. Its findings connect post-translational metabolic regulation with chemotherapy resistance and support further evaluation of succinylation-directed combination strategies.

• FLCN mRNA Rescue: From Mechanism to Translation

  2026-10-01

  Recent Birt-Hogg-Dubé research offers a compelling in vitro rationale for FLCN mRNA rescue. This thought-leadership guide connects that finding to RNA design, experimental validation, scalable T7 transcription, and the boundaries that still separate proof of concept from therapeutic translation.

• Dantrolene Sodium Salt in Calcium-Aware CRISPR

  2026-09-30

  Dantrolene sodium salt is best established as a potent, calmodulin-dependent ryanodine receptor antagonist. This thought-leadership perspective examines how controlled calcium signaling modulation could become a hypothesis-driven variable in CRISPR repair studies, while distinguishing established RyR biology from unvalidated genome-editing applications.

• Gastric Cancer Assembloids and Tumor–Stroma Biology

  2026-09-30

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal subpopulations from the same tissue. Their results show that stromal composition reshapes gene expression and drug sensitivity, providing a more informative platform for studying tumor heterogeneity, resistance, and individualized treatment responses.

• ELISA Stop Solution in Avian Vaccine Research

  2026-09-29

  ELISA Stop Solution is a critical endpoint reagent for converting enzyme-linked immunoassay chemistry into reproducible antibody data. This article connects endpoint control with the bivalent H5/H7 mRNA–LNP vaccine findings reported in SPF chickens and explains how to interpret binding-antibody results alongside neutralization and protection.

• PNU 74654: Wnt Signaling Pathway Inhibitor Workflows

  2026-09-29

  PNU 74654 provides a practical small-molecule entry point for testing Wnt/β-catenin signaling inhibition in cancer, stem cell, and differentiation models. This guide pairs product-specific handling with an evidence-aware workflow that separates pathway effects from solvent toxicity, cell-state changes, and assay artifacts.

8726 records 1/582 page Next 12345 下5页 Last page